Key Takeaways
- Pharma and Paints drove the quarter: Pharma packaging grew 37% YoY in Q4 and over 200% for the full year, while the Paint segment rebounded with 14.4% value growth as Asian Paints turned positive and Grasim scaled rapidly.
- Consolidation delivered a margin step-up: Shrinking five Hyderabad plants into two lifted EBITDA per kg from 37.6 to 40.7, an 8.4% jump, with the full annualized benefit of roughly ₹1/kg still to come in FY27.
- A lost client and a machine overhaul created near-term cost noise: BPCL lubes business, worth over ₹14-15 cr annually, was surrendered on price, while mandatory 30% recycled plastic forced a one-time maintenance spend on screw systems across machines.
- Management is guiding for a 20% EBITDA jump in FY27: The ₹210 cr target rests on volume growth of 10-13%, value growth of 13-15%, and EBITDA per kg reaching 42.5-43, all funded by brownfield expansions from internal accruals.
- What to watch next quarter: Whether the full raw material price pass-through from late March lifts Q1 margins as promised, the pace of Panipat capacity utilization toward the 40-50% target, and any commercial traction from the Vibe collaboration now that pilot molds are ready.
Segment Performance
- Pharma packaging: Grew 37% YoY in Q4 and over 200% for FY26, driven by product range expansion, faster new-pack development, and replacement demand from pharma companies pursuing expansion after export sanctions were removed.
- Paint segment: Recovered to 14.4% value and 13.5% volume growth in Q4, led by ABG (Grasim) jumping 60% versus the prior-year quarter and Asian Paints turning positive at 17% after being negative through Q3. Berger and Nerolac contributed only from the last 15 days of March when supply-chain fears spiked.
- Lubes: Declined after losing the BPCL client, which previously contributed over ₹14-15 cr annually, because the tendering system forced pricing Mold-Tek could not match. Private-sector clients who value quality and consistency remain, and the segment is expected to sustain at current levels.
- Thin wall (Food & FMCG): Grew 15.4% in value, driven by existing clients like Milky Mist, Hudson, Walko and Kwality Wall's growing double digits, plus new capacity and client additions from the Panipat plant.
- Client retention during price hikes: 98-99% of clients are blue-chip and cannot reduce their market presence; only 4-7% of sales go to non-blue-chip clients, where potential loss is capped at 1-2%.
Lakshmana Rao: "On the contrary to your expectation, in fact, we are finding our clients coming back in herds because they are worried about the connectivity, material procurement abilities, and ability to quickly react to the international scenario."
Margin Drivers & Cost Headwinds
- Hyderabad consolidation: Five plants reduced to two (Annaram and Sultanpur), completed by January/February this year, improved efficiencies, reduced overhead and cut goods-movement costs. The full annualized benefit of roughly ₹1/kg will reflect in FY27.
- RCP mandate impact: The mandatory 30% recycled plastic content, rising to 40% from next April, forced severe preventive maintenance and replacement of machine screws and parts to handle the mix, a one-time cost taken to the P&L. Pharma and Food are exempted from the mandate.
- Raw material pass-through: A 25-30% polypropylene price increase was passed on completely to clients, but only became effective in the last two weeks of March; full realization will show in Q1 FY27. Clients have also shortened raw material fluctuation correction periods from quarterly to monthly or fortnightly.
- Cost controls: Finance and HR admin teams have been created at all units to monitor and control cost elements, supporting the guided EBITDA per kg expansion to 42.5-43 in FY27 and 43-44 in FY28.
Lakshmana Rao: "So going forward with the only brownfield expansions, which will marginally may require capital, but increase in the capacity utilization will kick in. So I look at very positively for '26-'27 and to aim at least 42.5 to 43 range for '26-'27."
Capacity Expansion & Capex
- FY27 capex plan: ₹80-85 cr, entirely from internal accruals, focused on brownfield expansions only. No debt increase is expected.
- Capacity by end FY27: Approximately 67,000-68,000 tons, possibly close to 70,000 tons.
- Panipat: A second building for Food & FMCG is ready with four machines; four more machines arrive in July. Thin-wall utilization is expected to rise from the current 20% to 40-50% on the larger capacity base.
- Pharma: Land acquired near the Sultanpur unit, with possession expected this month and construction starting immediately. Commercial production is targeted by the beginning of calendar year 2027, before the end of FY27, expanding capacity from roughly 1,500 tons to 2,500 tons.
- New Pharma products: Ophthalmic and nasal sprays, plus 2-3 new cap systems, are under development, with 5-10 new products in the pipeline every quarter.
- North plant addition: Expected to contribute ₹35-40 cr in new business from Qpack and Food combined in FY27, supported by recently signed large clients who were previously buying from competitors in that region.
Lakshmana Rao: "Be assured, we'll be widening our product range year after year and getting more and more deep into the Pharma sector in the coming years."
New Initiatives & Client Dynamics
- Vibe collaboration: A long-term opportunity for high-end chemicals and lubricants closures. Two of three products have pilot molds ready, but the project remains in the developmental stage, with commercial revenue likely toward the end of FY27, roughly 2-3 quarters out.
- Grasim ramp: Grasim plants are now running at roughly 65% utilization versus the 50s last year, and management expects strong double-digit growth to continue for the next couple of years, supported by the Mahad plant being established.
- Asian Paints recovery: After being negative through Q3, Asian Paints delivered over 17% Q4-to-Q4 growth, and double-digit growth is expected in coming years.
- Reliance supply: Polypropylene production resumed from mid-March with assurance of no shortfall, easing a key raw material risk.
- Working capital: Higher inventory from purchasing at elevated prices in the last three weeks of March, plus Pharma's requirement to hold three months of material with 90-110 day payment cycles, stretched working capital.
ROCE Recovery Path
- The drag: Greenfield investments over the last three years elevated the capital base while capacity utilization lagged, depressing returns.
- The inflection: Capacity utilization crossed 50-60% this year and is expected to reach 70%+ from FY27 onward as those assets begin yielding to the bottom line.
- Guided trajectory: ROCE is expected to reach 13.5-14% in FY27 and roughly 15% in FY28, driven by brownfield-only capex and rising utilization rather than new greenfield commitments.
Lakshmana Rao: "That was when all these greenfield projects have been started, investments have shot up in the last 3 years. And these investments start yielding now. This year, I would say they crossed 50% to 60% capacity utilization. But next year onwards, I'm confident it will be 70% plus, and they will be yielding to the bottom line."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue | Cross ₹1,000 cr | FY27 |
| Value growth | 13% to 15% | FY27 |
| Volume growth | 10% to 13% | FY27 |
| EBITDA | At least ₹210 cr (20% growth from ₹173 cr) | FY27 |
| EBITDA per kg | 42.5 to 43 range | FY27 |
| EBITDA per kg | 43 to 44 range; possibly 44-45 if Pharma performs well | FY28 |
| ROCE | 13.5% to 14% | FY27 |
| ROCE | ~15% | FY28 |
| Pharma revenue | ₹50-55 cr (50% growth over FY26) | FY27 |
| Pharma capacity | Expand from ~1,500 tons to 2,500 tons | FY27 |
| Pharma new plant | Commercial production | Beginning of calendar year 2027 (before end FY27) |
| Food & FMCG growth | At least 20% including North | FY27 |
| Panipat thin-wall utilization | From 20% to 40-50% | FY27 |
| ABG Panipat utilization | From ~60% to 70%+ | FY27 |
| North plant new business | ₹35-40 cr from Qpack and Food combined | FY27 |
| Vibe commercial revenue | First revenue | Towards end of FY27 (2-3 more quarters) |
| Capex | ₹80-85 cr, brownfield only, from internal accruals | FY27 |
| Debt | No increase expected | FY27 |
| Gross margins | Maintain 46-47% levels | FY27 |
| Revenue | Easily cross ₹1,200 cr (per an analyst's math, management said "I hope so") | FY28 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue growth | 13.4% YoY for FY26 |
| Pharma revenue | ₹34.4 cr for FY26, +219% YoY |
| Pharma revenue growth (Q4) | +37% YoY |
| Paint segment value growth | 14.4% YoY |
| Paint segment volume growth | 13.5% YoY |
| Asian Paints growth (Q4) | +17% YoY |
| ABG (Grasim) volume growth (Q4) | +60% YoY |
| Food and FMCG growth | >15% YoY |
| Qpacks growth | 25% YoY |
| IML mix (volume) | 75.5% in Q4, 75.13% for FY26 |
| IML mix (value) | 76.8% for FY26 |
| EBITDA per kg | ₹40.7 for FY26, up from ₹37.6, +8.4% YoY |
| EBITDA per kg guidance (FY27) | ₹42 to ₹43, aiming at 42.5 |
| EBITDA guidance (FY27) | At least ₹210 cr, up 20% from ₹173 cr in FY26 |
| Total capacity | 63,000 MTPA, utilization ~43,000 tons |
| Capacity by end FY27 | ~67,000 to 68,000 tons, possibly close to 70,000 tons |
| Capex FY26 | ₹120 cr |
| Capex guidance FY27 | ₹80 cr to ₹85 cr |
| Cash generation FY26 | ~₹123 cr, net cash accruals ~₹100 cr after ~₹20 cr dividend |
| ROCE | 12.4% for FY26, up from 10.2% |
| ROCE guidance FY27 | 13.5% to 14% |
| Raw material price (polypropylene) | ₹145 to ₹150/kg currently, from ₹105/kg in early March, peaked at ₹160/kg |
| Gross margin | 46% to 47%, maintained |
| Pharma capacity | ~1,500 tons, targeting 2,500 tons in FY27 |
| Pharma volume FY26 | 853 tons |
| Pharma volume guidance FY27 | 1,200 to 1,300 tons |
| Pharma revenue guidance FY27 | ₹50 cr to ₹55 cr |
| Grasim (ABG) capacity | 12,000 tons (Panipat 5,000, Cheyyar 4,400, Mahad 2,500) |
| Grasim capacity utilization | ~65%, up from 50s last year |
| Panipat thin wall capacity utilization | 20% to 25% |
| Panipat thin wall capacity post July | 2,000 to 2,500 tons per annum including Qpack, doubling from ~1,000 tons |
| North plant (Qpack + Food) March sales | ~₹3 cr to ₹3.5 cr |
| North plant potential FY27 addition | ₹35 cr to ₹40 cr |
| Revenue guidance FY27 | ₹1,000 cr+, 13% to 15% value growth |
| Volume growth guidance FY27 | 10% to 13% |
| Lubes share of turnover | 17% to 18% |
| BPCL lost revenue | >₹14 cr to ₹15 cr per year previously |
| Raw material inventory coverage | ~2 months |